Pancreatic Cancer Clinical Trial
— CWS_ItaOfficial title:
The Italian Version of the Cancer Worry Scale . A Pancreatic Context Adaptation and Reliability Analysis
An Italian language version of the Cancer Worry Scale is not available yet.
The aim of this study is to develop and validate the Italian version of Cancer Worry Scale
through subjects at high risk of pancreatic cancer for familiarity/genetic predisposition, or
suffering from premalignant cystic lesions.
Status | Not yet recruiting |
Enrollment | 50 |
Est. completion date | August 31, 2020 |
Est. primary completion date | June 30, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Subject will be recruited from the current outpatients' clinic activity of the General and Pancreatic Surgery Unit, Pancreas Institute, Verona University Hospital. Subjects must be able to read and write in Italian. After obtained informed consent we will ask them to participate to preliminary pilot phase. The interview of the pilot group will be audio recorded to allow to investigate and track detail that will highlight the comprehension of scale and participants' suggestion. Patients affected by cynic neoplasm (group A) and high risk subjects for familiarity/genetic predisposition (group B) are currently enrolled at General and Pancreatic Surgery Unit of the Pancreas Institute of the University of Verona. Group A Patients with premalignant lesions (such as intraductal papillary mucinous neoplasms) that are followed-up at our Institution, to detect any clinic-radiological progression. Subjects older than 18 will be enrolled. Group B The enrolment criteria were the following : - Having at least 45 years of age or 10 years younger than the age of the youngest relative with pancreatic cancer (only for subject with familiar history of pancreatic cancer) - Having at least 40 years of age or 5 years younger than the age of the youngest relative with pancreatic cancer (only for subject with familial pancreatitis and subject affected by Lynch syndrome with at least one relative first- or second-degree affected by pancreatic cancer and subject having a known genetic mutation with at least a first-degree relative or a second-degree relative affected by pancreatic cancer - Having at least 30 years of age for subject with Familial Multiple Melanoma Syndrome - Having at least 30 years of age for patients affected by Peutz-Jeghers syndrome. The interview of pilot group will be record to allow us to investigate and track detail that will highlight the comprehension of cancer worry scale and participants' suggestion. Exclusion Criteria: - patients who not meet eligibility criteria |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Azienda Ospedaliera Universitaria Integrata Verona |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Syntactic and semantic equivalence of Cancer worry scale' items between English and Italian language and vice versa | the Syntactic and semantic equivalence of scale between two languages will be verified through the evaluation of differential item functioning analysis | 1 month | |
Secondary | Face Validity of cancer worry scale on Italian subjects | Face Validity will be measured through the evaluation of Clarity/ comprehensibility of each item of cancer worry scale (format and meaning) | 6 months | |
Secondary | Exploratory comparison between Patients Health Questionnaire and Irritability Depression Anxiety Scale and cancer worry scale | the comparison will be done considering the total score of scales | 9 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
Recruiting |
NCT06054984 -
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Terminated |
NCT03140670 -
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
|
Phase 2 | |
Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT05168527 -
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05391126 -
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
|
N/A | |
Terminated |
NCT03300921 -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT03153410 -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
|
Early Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05679583 -
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04183478 -
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
|
Phase 2/Phase 3 | |
Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
Completed |
NCT04290364 -
Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
|